Nodality, Inc. Announces Data Presentations at AACR 2013 Annual Meeting

Single Cell Network Profiling (SCNP) Technology Demonstrates Successful Applications in Blood and Lung Cancers

Nodality, Inc., a next-generation life sciences company partnering with leading firms to advance precision medicine, announced today results of the Company's Single Cell Network Profiling (SCNP) technology as reported in two poster presentations at the 104^th Annual Meeting of the American Association for Cancer Research (AACR), held in Washington, DC this week. SCNP provides the core foundation for Nodality's programs dedicated to improve clinical medicine by increasing the productivity of therapeutic R&D programs, enhancing life cycle management for commercialized drugs, and introducing new predictive diagnostics. The presented results showed that in single, functioning cells SCNP can characterize (beyond what is achievable with current molecular tools) the activity of potential therapeutic agents for mast cell leukemia (MCL) and non-small cell lung cancer (NSCLC).

Laura Brege, Nodality's President and Chief Executive Officer, commented, “We are excited to showcase at a leading oncology meeting such as AACR the results of our SCNP technology, a uniquely powerful tool for revealing functional biology which is relevant to drug discovery, clinical development and patient management. These are the first findings we have reported in MCL in a peer-reviewed forum, extending our previous successful programs in blood cancers, including in acute myelogenous leukemia and chronic lymphocytic leukemia. Furthermore, NSCLC is now the second cancer indication beyond bladder cancer in which we have reported application of our technology to cancer epithelial cells not collected from blood samples. These results further validate SCNP as a broadly enabling platform to provide clinically actionable information critical for drug developers, clinicians and patients.”

• In a presentation titled, “Functional characterization of KIT and FcεR1 receptor mutations in Mast Cell Leukemia using Single Cell Network Profiling (SCNP)” (Abstract Number 3524), researchers at Long Island Jewish Health System, Cold Spring Harbor Laboratory and Nodality demonstrated that SCNP can characterize signaling and drug sensitivity/resistance profiles in MCL bone marrow mast cells and potentially inform therapeutic selection. New approaches to treatment are needed for this highly aggressive blood cancer, and Nodality intends to expand this research, including assessing cell-type specific differences in drug response using SCNP.
• In a presentation titled, “Quantitative measurements of EGFR pathway signaling and modulation in pleural effusion samples from non-small cell lung cancer (NSCLC) patients using single cell network profiling (SCNP)” (Abstract Number 3523), researchers at Long Island Jewish Health System and Nodality showed that SCNP can be used to characterize epithelial cancer cells drawn from pleural effusions and measure metabolic activity of a small molecule agent. Previously, researchers demonstrated that SCNP can be used to characterize epithelial cancer cells drawn from bladder washes in bladder cancer patients.

Alessandra Cesano, M.D., Ph.D., Chief Medical Officer of Nodality, stated, “Based on these and other results, we are continuing to investigate the feasibility of extending SCNP analyses to alternative tissue sources such as fine needle aspirates, ascites fluid, bladder washes and circulating tumor cells from peripheral blood. We anticipate these additional applications of SCNP will be able to provide important information for both prognostic and response predictive utility in diverse solid tumor indications.”

About Nodality

Nodality is a next-generation life sciences company that is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to reveal biology, define disease, and improve health. Nodality's unique, innovative, and proprietary platform, Single Cell Network Profiling or SCNP, enables the promise of precision medicine by unlocking the potential of therapeutics and by matching therapies with the right patients. SCNP enables functional characterization of disease-associated signaling at the individual patient level, enabling optimization of treatment tailored to target the biology driving the disease. Nodality is applying SCNP to develop molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the lead products targeting treatment management in hematological malignancies. Nodality is also collaborating with Pharma partners on patient stratification & companion diagnostics development, drug & disease profiling, determination of mechanism of action, mechanism-based competitive differentiation, whole blood PD assays, and biomarker discovery & development. These applications can result in increased probability of success, reduced timeline for clinical development, and differentiation from competitors in the marketplace. Nodality established multi-year pharma strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB) and Pfizer (NYSE: PFE) in 2012, utilizing its SCNP technology to assist the development of several compounds focusing initially on immunology disorders.

About Single Cell Network Profiling

Single Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signaling networks in immunology and cancer. SCNP, by measuring functional signaling network behavior at the level of the single cell, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of functional cellular heterogeneity in otherwise molecularly and phenotypically homogeneous tissues, including the identification of rare cell subsets such as drug-resistant and stem cells. As such, the technology has widespread application in preclinical drug development, clinical drug development and diagnostic development.